

T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL)

Amgen-sponsored satellite symposium at EHA2024 Hybrid Congress

Chaired by **Jesús María Hernández Rivas (Spain)** and **Hervé Dombret (France)**

Thursday, 13 June 2024, 08.00–09:30 CEST

Hall N101
IFEMA Madrid Recinto Ferial, Madrid, Spain



ADD A REMINDER
TO YOUR CALENDAR

FACULTY



Jesús María Hernández Rivas
(Spain)



Hervé Dombret
(France)



Selina Luger
(USA)



Alessandro Rambaldi
(Italy)



Martin Schrappe
(Germany)



Nicola Gökbuget
(Germany)

PROGRAMME

T-cell engaging immunotherapy in early treatment of B-cell acute lymphoblastic leukemia (B-ALL)

Chaired by: Jesús María Hernández Rivas (Spain) and Hervé Dombret (France)

Welcome and introduction

Jesús María Hernández Rivas (Spain)

The role of T-cell engaging immunotherapy in the frontline therapy of adult B-ALL treatment

Selina Luger (USA)

Innovative approaches in Ph-positive B-ALL: towards a chemo-free approach

Alessandro Rambaldi (Italy)

Novel approaches in pediatric populations

Martin Schrappe (Germany)

Panel discussion and future perspectives

Hervé Dombret (France); Selina Luger (USA); Alessandro Rambaldi (Italy);
Martin Schrappe (Germany); Nicola Gökbuget (Germany)

Conclusion and remarks

Hervé Dombret (France)